Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LY2787106 · 1 trial · 1 indication
Number of participants with one or more treatment emergent adverse event (TEAE) or any Serious AE (SAE). A summary of SAEs and other non-serious AEs, regardless of causality, is located in the Reported Adverse Event module.
This analysis assesses the mean change in Hemoglobin from baseline to the end of Cycle 4. The analysis was carried separately for Cohort B1 without supplemental iron and Cohort B2 with supplemental iron.
| Arm | Type | Description |
|---|---|---|
| LY2787106 Dose Escalation | EXPERIMENTAL | Part A: Dose escalation starting at 0.3 milligram/kilogram (mg/kg), intravenously (IV), day one of up to three 21-day cycles. |
| 10 mg/kg LY2787106 | EXPERIMENTAL | Part B: 10 mg/kg of LY2787106, administered IV, on day one of up to eight 7-day cycles. Participants who do not experience a stopping rule and who are felt to be benefiting during the defined treatment period may receive additional doses at the discretion of the investigator. |
| 10 mg/kg LY2787106+Iron | EXPERIMENTAL | Part B: 10 mg/kg of LY2787106, administered IV, on day one of up to eight 7-day cycles with daily oral iron supplementation. Participants who do not experience a stopping rule and who are felt to be benefiting during the defined treatment period may receive additional doses at the discretion of the investigator. |
| Name | Type | Description |
|---|---|---|
| LY2787106 | DRUG | Administered IV. |
| Iron Supplementation | DIETARY_SUPPLEMENT | Administered orally. |
Inclusion Criteria: * Have histological or cytological evidence of non-myeloid cancer (solid tumors, lymphomas or multiple myeloma) that is metastatic and/or incurable * Have been treated with at least one systemic (oral, intravenous, or subcutaneous) anti-cancer therapy or regimen * Have a hemoglo...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Bristol-Myers Squibb Company | BMY | 2 | PHASE3 | Luspatercept |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 2 | PHASE3 | Elritercept |
| Disc Medicine, Inc. | IRON | 2 | PHASE2 | DISC-0974 |
| Akebia Therapeutics, Inc. | AKBA | 2 | PHASE3 | Vadadustat |
| Ascentage Pharma Group International Unsponsored ADR | AAPG | 1 | PHASE1 | APG-5918 |
| Bayer | BAYRY | 1 | - | Molidustat |
LY2787106 is an investigational small molecule being studied for the treatment of anemia, including anemia in patients with cancer. It has been evaluated in a Phase 1 clinical trial and is not approved for any indication. Eli Lilly and Company is the developer.
LY2787106 targets HAMP, also known as hepcidin. It is an inhibitor of this target. By inhibiting hepcidin, the drug is designed to affect iron regulation, which is relevant to anemia. The target class is an inhibitor, and the molecule is a small molecule.
LY2787106 is developed by Eli Lilly and Company, which trades on the New York Stock Exchange under the ticker LLY. The company is responsible for the clinical development of this investigational anemia therapy.
LY2787106 is in Phase 1 clinical development. It has completed one Phase 1 trial and has no active trials. The drug is investigational and has not been approved by the FDA for any indication.
LY2787106 has been studied in one completed Phase 1 trial, NCT01340976, titled A Phase 1 Study of LY2787106 in Cancer and Anemia. The trial enrolled 33 participants in the United States and included adults 18 years and older.